ATE406453T1 - Verfahren zür einführung und expression von genen in tierischen zellen - Google Patents

Verfahren zür einführung und expression von genen in tierischen zellen

Info

Publication number
ATE406453T1
ATE406453T1 AT96912850T AT96912850T ATE406453T1 AT E406453 T1 ATE406453 T1 AT E406453T1 AT 96912850 T AT96912850 T AT 96912850T AT 96912850 T AT96912850 T AT 96912850T AT E406453 T1 ATE406453 T1 AT E406453T1
Authority
AT
Austria
Prior art keywords
animal cells
genes
introduction
expression
gene
Prior art date
Application number
AT96912850T
Other languages
English (en)
Inventor
Robert Powell
George Lewis
David Hone
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23721539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406453(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE406453T1 publication Critical patent/ATE406453T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96912850T 1995-05-03 1996-04-24 Verfahren zür einführung und expression von genen in tierischen zellen ATE406453T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/433,790 US5877159A (en) 1995-05-03 1995-05-03 Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same

Publications (1)

Publication Number Publication Date
ATE406453T1 true ATE406453T1 (de) 2008-09-15

Family

ID=23721539

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912850T ATE406453T1 (de) 1995-05-03 1996-04-24 Verfahren zür einführung und expression von genen in tierischen zellen

Country Status (8)

Country Link
US (1) US5877159A (de)
EP (1) EP0827410B1 (de)
JP (3) JP3629274B2 (de)
AT (1) ATE406453T1 (de)
AU (1) AU706104B2 (de)
CA (1) CA2219994A1 (de)
DE (1) DE69637660D1 (de)
WO (1) WO1996034631A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6150170A (en) * 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7045336B1 (en) 1995-09-06 2006-05-16 The United States Of America As Represented By The Secretary Of The Army Bacterial delivery system
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
CA2218754A1 (en) * 1996-11-15 1998-05-15 Eli Lilly And Company Recombinant psa expression vectors and assays using the same
AU6868198A (en) * 1997-03-28 1998-10-22 Jason C. Grove Antimicrobial mediated bacterial dna delivery
AU5756298A (en) 1997-04-18 1998-11-13 Gesellschaft Fur Biotechnologische Forschung Mbh Attenuated salmonella strain used as a vehicle for oral immunization
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
WO1999013053A1 (en) * 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1021548A1 (de) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Verfahren zür einführung und expression von rna in tierischen zellen
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
US6143551A (en) * 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
WO2000061184A2 (en) * 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
CA2370628A1 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
GB9918283D0 (en) * 1999-08-03 1999-10-06 Int Centre Genetic Eng & Bio Hsv vaccines
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001031046A1 (en) * 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
US20020051791A1 (en) * 1999-12-22 2002-05-02 Galloway Darrel R. Methods for protection against lethal infection with bacillus anthracis
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (de) * 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
US7083858B1 (en) 2000-07-26 2006-08-01 Worthen Industries, Inc. Thermally activated adhesive films for the collation of wire staples
EP1315816B1 (de) 2000-09-08 2010-12-29 University Of Maryland Biotechnology Institute Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen
GB0024203D0 (en) * 2000-10-03 2000-11-15 Peptide Therapeutics Ltd Stabilisation of plasmid inheritance in bacteria
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20050180985A9 (en) * 2001-10-04 2005-08-18 Vladoianu Ion R. Live attenuated salmonella strains for producing monovalent or multivalent vaccines
US20030224444A1 (en) * 2002-02-25 2003-12-04 Sabbadini Roger A. Antibodies to native conformations of membrane proteins
US20030224369A1 (en) * 2002-02-25 2003-12-04 Surber Mark W. Reverse screening and target identification with minicells
US20030207833A1 (en) * 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
CA2380471A1 (en) * 2002-02-28 2003-08-28 The University Of Hong Kong Oral dna vaccine composition for hepatitis b virus chronic infection
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
CA2486118A1 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
WO2004050829A2 (en) * 2002-08-20 2004-06-17 Aeras Global Tuberculosis Vaccine Foundation Recombinant double-stranded rna phage, and use of the same
EP1537214B1 (de) * 2002-09-01 2006-03-01 Washington University Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004084936A2 (en) * 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
DK1592441T3 (da) * 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
DE10326189A1 (de) * 2003-06-06 2005-01-05 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Bakterielle Träger für Nukleotidsequenzen kodierend für Wirkstoffe
EP2284268A3 (de) 2003-06-12 2012-05-30 Alnylam Pharmaceuticals Inc. Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
WO2005040388A2 (en) * 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
US20060002956A1 (en) * 2004-04-05 2006-01-05 Surber Mark W Minicells as vaccines
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
EP1789094B1 (de) * 2004-08-13 2014-12-10 MARSHALL, Barry J. Bakterielles abgabesystem
US7985581B2 (en) 2004-08-23 2011-07-26 Alnylam Pharmaceuticals, Inc. Multiple RNA polymerase III promoter expression constructs
EP2772541A3 (de) 2004-09-24 2014-09-24 Alnylam Pharmaceuticals Inc. Targeting von Zwischenprodukten zur Gegenstrangreplikation von Hepatitis C Virus durch RNAi
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
EP2266602A3 (de) 2004-11-01 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Kombinationswege zur Erzeugung von Immunantworten
DE602005027747D1 (de) 2004-12-22 2011-06-09 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
WO2006076517A1 (en) * 2005-01-12 2006-07-20 Albert Einstein College Of Medicine Of Yeshiva University Attenuated mycobacteria as vectors for gene delivery to mammalian cells
EP2224008A3 (de) 2005-05-12 2010-12-01 Murdoch University Gene und Proteine aus Brachyspira Hyodysenteriae und deren Verwendung zur Diagnose und Therapie
US9708619B2 (en) 2005-09-20 2017-07-18 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRNA
EP2056849A4 (de) * 2006-08-04 2010-09-08 Univ Pennsylvania Verfahren und zusammensetzungen zur behandlung von ige-vermittelten erkrankungen
EP2061800B1 (de) * 2006-08-15 2015-07-29 The Trustees of the University of Pennsylvania Zusammensetzungen mit hmw-maa und fragmenten davon sowie verfahren zu ihrer verwendung
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2185578A2 (de) 2007-08-03 2010-05-19 Spirogene Pty Ltd Gene und proteine von brachyspira hyodysenteriae und anwendungen davon
CN101139616B (zh) * 2007-08-16 2011-04-06 湖北大学 一种高通量的通过细菌直接侵染将外源基因导入昆虫细胞的方法
US9051557B2 (en) * 2007-09-12 2015-06-09 Intervet International B.V. Method for continuously culturing Ehrlichia canis
PT2190980T (pt) 2007-09-12 2016-10-07 Intervet Int Bv Métodos de cultura da espécies bacterianas da família das anaplasmatáceas
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2363407A1 (de) 2008-02-28 2011-09-07 Murdoch University Neuartige Brachyspira-Sequenzen, immunogene Zusammensetzungen, Herstellungsverfahren dafür und Verwendung davon
US8460681B2 (en) 2008-03-27 2013-06-11 Prionics Ag Sequences of Brachyspira, immunogenic compounds, methods for preparation and use thereof
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2853269B1 (de) 2008-05-19 2019-05-01 Advaxis, Inc. Doppeltes Freisetzungssystem für heterologe Antigene umfassend einen rekombinanten Listeria - Stamm, attenuiert durch Mutation von dal / dat und Deletion von ActA, umfassend ein Nukleinsäuremolekül, das ein Listeriolysin O - Prostata - spezifisches Antigen - Fusionsprotein codiert
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010102140A1 (en) 2009-03-04 2010-09-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
BRPI1003750A2 (pt) 2010-07-22 2012-04-10 Univ Sao Paulo microrganismos recombinantes, métodos de preparação de linhagens vacinais, antìgenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
EP2447277A1 (de) 2010-10-28 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Impfstoffzusammensetzungen auf Basis von modifizierten gp41-Immunogenen
EP3527222B1 (de) 2011-02-15 2021-04-07 Vaxiion Therapeutics, LLC Therapeutische zusammensetzungen und verfahren für auf antikörper- und fc-haltigen molekülen basierende gezielte verabreichung bioaktiver moleküle durch bakterienminizellen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2012129295A1 (en) 2011-03-21 2012-09-27 Vaxin Inc. Rapid and prolonged immunologic-therapeutic
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
KR20140134695A (ko) 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해
KR20190110645A (ko) * 2012-09-06 2019-09-30 에벨리큐어 바이오테크놀로지스 게엠베하 신규의 약독화된 시겔라 생백신
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP2020519309A (ja) 2017-05-10 2020-07-02 アルバジュナ・セラピューティクス・エセ・エレ 高い二重のＨＩＶ抗ウイルス及び免疫調節活性を有するＦｃ融合タンパク質誘導体
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
WO2024151767A2 (en) * 2023-01-12 2024-07-18 Health Science Funding, LLC Solid tumor therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DE3517656A1 (de) * 1984-05-18 1985-11-21 International Genetic Sciences Partnership, Research Triangle Park, N.C. Verfahren zur herstellung von makromolekuelen durch dna-transformation
IL79432A (en) * 1985-07-31 1992-05-25 Univ Leland Stanford Junior Unicellular microorganisms having invasive capability due to exogenous inv gene and vaccines comprising such microorganisms
ATE111957T1 (de) * 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.

Also Published As

Publication number Publication date
JP2003219877A (ja) 2003-08-05
AU5552796A (en) 1996-11-21
EP0827410A4 (de) 1999-05-12
DE69637660D1 (de) 2008-10-09
AU706104B2 (en) 1999-06-10
US5877159A (en) 1999-03-02
JP2005006659A (ja) 2005-01-13
JP3629274B2 (ja) 2005-03-16
WO1996034631A1 (en) 1996-11-07
JPH11505219A (ja) 1999-05-18
EP0827410A1 (de) 1998-03-11
CA2219994A1 (en) 1996-11-07
EP0827410B1 (de) 2008-08-27

Similar Documents

Publication Publication Date Title
DE69637660D1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
EP0400958A3 (de) Lebende Impfstoffe
DE50015772D1 (de) Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
DE69604686D1 (de) Methode zur modulation der genexpression mit reduzierter immunstimulierender wirkung
NO965080D0 (no) Antisens oligonukleotidmodulering av genekspresjon
CY1106926T1 (el) Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
ATE174599T1 (de) Bindungskompetente oligomere, die 2',5'-bindungen enthalten
ATE284898T1 (de) Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
DE59510466D1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
WO2003076561A3 (en) Recombinase fusion protein with enhanced cellular uptake
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
RU94046362A (ru) Последовательности днк, плазмиды, применение плазмиды, растения, бактерии, применение последовательности днк, дрожжевые штаммы
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ATE374038T1 (de) Verwendung von bakteriellen pard kis/pard kid toxin-antitoxin system zur tötung von eukaryotischen zellen
ATE247978T1 (de) Verwendung von ompa enterobakterproteinen um zielgerichtet antigen-präsentierende zellen anzusteuern
EP0527941A4 (de)
CY1108781T1 (el) Εμβολιο ψαριων
WO2000065063A3 (en) Nucleic acid vaccines against rickettsial diseases and methods of use
Morrison mRNA Vaccines and their impact on medicine.
FR2713658B1 (fr) Séquences d'acides nucléiques régulatrices et utilisations.
MX9708615A (es) Terapia de genes animales.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties